Pfizer(US:PFE) GLP1减重宝典·2025-10-01 03:04Core Insights - Metsera disclosed positive results from two Phase IIb weight loss trials (VESPER-1 and VESPER-3) for MET-097i, a novel GLP-1 receptor agonist with potential for once-monthly administration [4] - The trials are designed to evaluate weight loss efficacy and safety, with VESPER-1 showing significant weight reductions compared to placebo [6] - Pfizer has agreed to acquire Metsera, which will enhance its portfolio with differentiated GLP-1 and non-GLP-1 candidates [4] Group 1: Trial Results - VESPER-1 included 239 participants and assessed MET-097i at doses ranging from 0.4mg to 1.2mg, showing average weight reductions of -8.1%, -10.0%, -13.0%, and -14.1% respectively, with the highest individual reduction in the 1.2mg group reaching -26.5% [6] - VESPER-3 is ongoing with 268 participants, focusing on the efficacy and tolerability of multiple monthly doses, with results expected at future milestones [4][6] Group 2: Acquisition and Strategic Implications - Pfizer's acquisition of Metsera, approved by both boards, aims to leverage Metsera's technological advancements and diverse drug candidates, potentially leading to best-in-class efficacy and safety [4] - The acquisition is expected to strengthen Pfizer's position in the GLP-1 market, which is rapidly evolving with new therapeutic options [4]